Society

From lab to patient: Why European biotech is at a crossroads

Innovation only succeeds when it demonstrably creates value for both patients and the healthcare system. How can biotech and pharmaceutical players design their R&D strategies so that medical innovation reaches patients faster, more precisely, and in an affordable way? An interview with Jérôme Van Biervliet and Frank Hulstaert.

Inside the science of endometriosis-associated pain

An Interview with Eleonora Persoons from the Vriens/Voets Lab and Vaidi Plovie from Endo.Insideout vzw

Two labs, one question: MAGISTER begins

First laureates of the Fund Stéphanie Willems (King Baudouin Foundation), tackling glucocorticoid resistance in polymyalgia rheumatica (PMR) and giant cell arteritis (GCA)

From discovery to diagnosis: turning research insights into tools for patients

An interview with Siele Ceuppens, Senior Scientist at VIB Discovery Sciences

Biotalys: Bringing protein-based crop protection to the field

US EPA approval for EVOCA™ stands as a major validation

2025 in review: The best of the VIB blog

As the year comes to an end, we take a look back at all we've published on this blog and share some of our (and your!) favorites.

Road to PMA approval of Biocartis’ Idylla™ CDx MSI Test

Powered by VIB science

Confo Therapeutics: unlocking the power of GPCRs

Anna Dumitriu starts bioart residency in neuroscience at VIB-KU Leuven

When scientists and politicians meet: The politician’s perspective

A conversation with politician Toon Vandeurzen, who visited the VIB-KU Leuven Center for Brain & Disease Research as part of the Science meets Parliament program

From first families to first trials

Julie van der Zee on biobanking, trust, and the long road from discovery to intervention

When scientists and politicians meet: The researcher’s perspective

Let’s talk with Zoë Van Acker, who participated in the Science Meets Parliament Program and got paired up with politician Toon Vandeurzen